Cargando…

The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study

The androgen receptor (AR) and its signaling pathway play an important role in the development and progression of prostate cancer (PCa). In the setting of primary treatment of PCa with radiotherapy (RT), where the AR can be expected to be of more importance, studies evaluating the AR expression are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poelaert, Filip, Van Praet, Charles, Beerens, Anne-Sophie, De Meerleer, Gert, Fonteyne, Valérie, Ost, Piet, Lumen, Nicolaas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352440/ https://www.ncbi.nlm.nih.gov/pubmed/25793207 http://dx.doi.org/10.1155/2015/812815

Ejemplares similares

Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
por: Fonteyne, Valérie, et al.
Publicado: (2012)

Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
por: Claeys, Tom, et al.
Publicado: (2015)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
por: Decaestecker, Karel, et al.
Publicado: (2014)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
por: De Bleser, Elise, et al.
Publicado: (2020)

Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis
por: Vermassen, Tijl, et al.
Publicado: (2015)

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial
por: Fonteyne, Valérie, et al.
Publicado: (2017)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
por: De Wolf, Katrien, et al.
Publicado: (2017)

Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients
por: EL-SAGHIRE, HOUSSEIN, et al.
Publicado: (2014)

Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?
por: Helsmoortel, Hetty, et al.
Publicado: (2018)

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy
por: De Wolf, Katrien, et al.
Publicado: (2015)

Is It Safe to Switch from a Standard Anterior to Retzius-Sparing Approach in Robot-Assisted Radical Prostatectomy?
por: Lambert, Edward, et al.
Publicado: (2023)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients
por: Huysse, Wouter, et al.
Publicado: (2017)

Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up
por: De Visschere, Pieter, et al.
Publicado: (2016)

Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study
por: Fonteyne, Valérie, et al.
Publicado: (2023)

Perineal Urethrostomy: Surgical and Functional Evaluation of Two Techniques
por: Lumen, Nicolaas, et al.
Publicado: (2015)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study
por: Wu, Jun-Xin, et al.
Publicado: (2016)

ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
por: Dal Pra, Alan, et al.
Publicado: (2023)

Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy
por: Danckaert, Willeke, et al.
Publicado: (2023)

Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine
por: Dhondt, Bert, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Prognostic Features of Near-Infrared Spectroscopy Following Primary Radical Prostatectomy
por: Vermassen, Tijl, et al.
Publicado: (2021)

Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium
por: Verghote, Flor, et al.
Publicado: (2023)

Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre
por: Peters, Cedric, et al.
Publicado: (2021)

Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study
por: Li, Youquan, et al.
Publicado: (2022)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
por: Pizurica, Marija, et al.
Publicado: (2023)

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer
por: Choi, Se Young, et al.
Publicado: (2021)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
por: Deek, Matthew P., et al.
Publicado: (2022)

A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer
por: De Kerf, Geert, et al.
Publicado: (2023)

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol
por: Rammant, Elke, et al.
Publicado: (2017)

Excision and Primary Anastomosis for Isolated, Short, Anastomotic Strictures in Transmen
por: Verla, Wesley, et al.
Publicado: (2020)

Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer
por: Reverberi, C., et al.
Publicado: (2020)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9bofbk14pi7tddh4thor2jouv6